The speakers provided a state-of-the-art overview of human exposure assessment techniques (especially applications of biological markers) and their relevance to human tissue specimen banking. Issues relevant to large-scale specimen banking were discussed, including program design, sample design, data collection, tissue collection, and ethical ramifications. The final group of presentations concerned practical experiences of major specimen banking and human tissue monitoring programs in the United States and Europe. The symposium addressed the utility and research opportunities afforded by specimen banking programs for future research needs in the areas of human exposure assessment, risk assessment, and environmental epidemiology. The third day of the symposium consisted of a small workshop convened to discuss and develop recommendations to the U.S. Environmental Protection Agency regarding applications and utility of large-scale specimen banking, biological monitoring, and biological markers for risk assessment activities. Environ Health Perspect 1 03(Suppl 3): 3-8 (1995) 
Background
Over the last 60 years, human technologies and activities have created and released an unprecedented diversity and quantity of toxic substances into the environment. As we have learned more about the actual and potential adverse effects of these pollutants on the global ecosystem, in general, and on human health, in particular, there has been a growing recognition of the need to monitor the release and subsequent movement of these substances through both the physical and biological components of the environment. In addition to the sampling and monitoring of the ambient outdoor environment for toxic pollutants, there has been an increasing interest in both the monitoring of (5, 6) .
Similarly, during the late 1960s and early 1970s, polychlorinated biphenyls (PCBs) were recognized as persistent environmental contaminants. Bioaccumulation of PCBs in plants and animals resulted in their concentration in the food chain to humans (7) and their detection in human tissues (8, 9) .
As these advances in exposure assessment were occurring, the field of environmental specimen banking was also progressing. Environmental specimen banking is the long-term, stable storage of specimens sampled from the physical environment, such as air, water, soil, or sediment samples, or of biological specimens sampled from human, animal, or plant populations (10) . Such specimens would be available to measure levels of environmental pollutants ( (12, 13) .
Historically, the U.S. Environmental Protection Agency (U.S. EPA) and a number of other government agencies have been interested in the use of human tissue specimens and specimen banks for biological monitoring (14 The objectives of this symposium were a) to provide a state-of-the-art overview of human exposure assessment techniques (especially applications of biological marker technology) and their uses in biological monitoring; b) to review advances in the design and implementation of human tissue specimen banking; and c) to synthesize and apply these techniques and advances to the development of tissue specimen banks well suited to future research needs in the areas of human exposure assessment, risk assessment, and environmental epidemiology. The symposium program was designed to approach these objectives initially from a theoretical perspective, followed by the more practical perspective of operating biological monitoring or specimen banking programs. The symposium program consisted of four sessions, each followed by a panel discussion with the symposium attendees. The first session began by addressing the opportunities that human tissue monitoring and specimen banking offer for research and public health practice in the areas of risk assessment, exposure assessment, and environmental epidemiology. The second session included four presentations on biological monitoring and exposure assessment. The third session dealt with design and methodological issues, including sample design and analysis, specimen collection, bank management, and ethical issues. In the fourth session speakers presented applications and practical experiences of ongoing biological monitoring and specimen banking programs in the United States and Europe. Finally, after the last formal presentation of the symposium, a small workshop was held to specifically consider the role of specimen banking in the process of risk assessment.
The Opportunities
The symposium opened with three presentations that addressed the utility and research opportunities afforded by biological markers used in biological monitoring and by specimen banking programs for present and future research needs in the areas of risk assessment (presented by Hal Zenick, HERL), human exposure assessment (presented by Ken Sexton, U.S. EPA), and environmental epidemiology in public health practice (presented by Lynn Goldman, currently at the U.S. EPA).
Dr. Zenick began his presentation with the observation that, while there is a multitude of biomarkers of exposure, effect, and susceptibility, the number which also meets stringent criteria of validation (21), proves to be practical in the field, and is suitable for banked specimens is somewhat small. Nevertheless, as this small number grows with continuing research, the utility of biomarkers to the risk assessment process also grows. The use of biomarkers of exposure in the exposure assessment process is obvious and biomarkers of effect may be useful in hazard identification, especially if these indicators can be detected at very low levels and are predictive of subsequent adverse health effects. Both types of biomarkers may be useful in dose-response estimations if there is sufficient understanding of the mechanistic (pharmacokinetic) link between the biomarker of exposure (indicative of dose) and the biomarker of effect (response). Biomarkers could also be particularly useful in making high-to-low dose extrapolations and in the study of interindividual variability.
Given the lessons learned from the shortcomings and design flaws of previous specimen banking efforts, careful definition of the target population and design of the sampling frame are essential for any specimen bank to be useful in risk assessment. For example, in this context, populations that are either highly exposed or highly susceptible to adverse health effects of the exposure would be of particular interest. The utility of any specimen bank to the risk assessment process will usually be retrospective in that it could reaffirm biological significance, predictive value, or dose-response relationships of biomarkers when their values can be compared to follow-up exposure and health outcome data. Specimen banking may also provide historical baseline data for defined populations or help identify new high risk groups with increased exposure or susceptibility.
Opportunities for research in human exposure assessment were presented by Ken Sexton in the framework of the U.S. EPA's National Human Exposure Assessment Survey (NHEXAS). The goal of NHEXAS is to use measurements and models to estimate exposures and dosages of important environmental pollutants in representative samples of the whole U.S. population and certain highly exposed or highly susceptible subpopulations and to study causes and trends of exposure through time and space. These estimates are usually based on measurements of pollutants in the immediate or general environments of potentially exposed humans; models of exposure and dose based on contact with the pollutant and pathways of uptake; and pharmacokinetic models of the pollutant in the body. Biomarkers and biological monitoring offer the opportunity to independently study the relationship between exposure and dose and to compare biomarker measurements with estimates derived from the environmental measurements and models. Three and DNA adducts of aflatoxin Bl, a potent liver carcinogen, he was able to validate their use in assessing recent dietary exposure to aflatoxin in a study in Gambia. The same molecular biomarkers were used in China to study the interaction between aflatoxin exposure and chronic hepatitis B virus infection as risk factors for primary liver cancer. The study showed that the relative risk for liver cancer associated with aflatoxin exposure alone was 4.8 and that it rose to 60.1 for people with both aflatoxin exposure and chronic hepatitis B virus infection.
The last presentation of this session was given by Stephen Rappaport (UNC-SPH) on the relationship between environmental monitoring and biomarkers in exposure assessment. He argued for the importance of measuring intraindividual variation of biomarkers and comparing it to the corresponding variation in exposure experienced by the same individual. A regression of the subjects' mean biomarker values on their mean environmental exposures would describe the biomarker-exposure relationship. A large correlation coefficient would indicate linear pharmacokinetics, small differences between individuals, and adequate sample sizes of intraindividual measurements, a small correlation coefficient would indicate the opposite. He then described a study which found that personal exposure monitoring of the subjects' immediate environment was a better measure than a number of biomarkers for studying the dose-response relationship. The underlying reason for this was that the ratio of within-subject to between-subject variance was much larger for the biomarkers compared to the personal monitoring measurements.
Design and Methodological Issues
With this session, the symposium began to turn to more practical issues of designing studies using biological monitoring or specimen banking. As mentioned above, a critically important design issue for any biological monitoring or specimen bank is the construction of its sampling design. Robert Murphy and Trena Ezzati-Rice, both from the National Center for Health Statistics, started this session by drawing from their experience with the National Health and Nutrition Examination Surveys (NHANES). It is generally desirable to have a probability sample of the members of a defined target population in which every member of the target population (i.e., the potential sample universe) has a known probability not equal to zero of being sampled. Use of probability sampling methods is necessary for large-scale biological monitoring studies so that results can be used to infer quantitatively exposures or health effects from the probability sample to the target population. Another important sampling issue is that of oversampling special populations, such as minorities and highly exposed or highly susceptible groups.
Issues relating to choice of bankable tissues, intra-and interindividual variation, and temporal variation of exposure biomarkers were addressed by George Lucier and Claudia Thompson, both from NIEHS. Advances in the areas of molecular genetics and molecular epidemiology now make it possible to study genetic polymorphisms of the enzymes used to metabolize xenobiotic compounds, presymptomatic genetic changes (e.g., somatic mutations) associated with increased risk disease, and other genetic markers of susceptibility. The capability of studying the RNA species present in tissue samples permits researchers to study tissue The third day of the symposium consisted of a small workshop of about 20 people discussing the specific implications of the proceedings of the previous 2 days for the process of human risk assessment. The purpose of the workshop was to develop recommendations to the U.S. EPA regarding the application and utility of large scale specimen banking (i.e., biological monitoring and storage of tissue specimens) as it applies to the risk assessment process at the U.S. EPA, and other government agencies. The group discussed the establishment of a National Human Tissue Bank and the impact that such a bank would have on the following three elements of the risk assessment process: exposure assessment, hazard identification, and dose-response estimation. Among the group's major recommendations was one that the National Academy of Sciences should conduct a follow-up study to their 1991 study of human tissue monitoring (20) . This new study would thoroughly investigate the objectives, design, and management of a National Human Tissue Bank. It was also recommended that the National Human Tissue Bank should be based on a national probability sample and that it be funded through a long-term, multiagency mechanism.
Conclusions
Biological monitoring, exposure assessment, and health effects surveillance make up the critical parts of the empirical data base necessary to understand and evaluate the impact of environmental pollutants upon the public health. The hierarchical goals of public health practice for the field of environmental health can be stated as: first, to prevent unacceptable toxic exposures from occurring in the first place; second, to reduce those toxic exposures that are judged to be unacceptable; and third, if the first two goals fail to be met, to identify and treat those whose health has been damaged by the toxic exposure (22) . Thus, exposure assessment is the key measure for evaluating the success or failure of public health intervention programs for preventing environmentally related diseases and for establishing associations between particular toxic exposures and those suffering the adverse health effects that need to be identified and treated.
Human tissue specimen banking can play an important role in these endeavors. Biological monitoring in connection with specimen banking can serve a critical sentinel function for environmental toxic exposures by early identification of specific toxic hazards, before toxic effects on health become apparent. Applications of pharmacokinetic data can provide a basis for the biological interpretation of observed concentrations of various environmental toxins in body fluids and tissues.
Specimen banking may also serve a fundamental purpose in facilitating research to establish associations between particular toxic exposures and adverse health outcomes. Having banked tissue specimens available makes it possible to assay both biomarkers of exposure and biomarkers of health effects in the same specimens from the same individual. The ability to collect this type of data greatly facilitates research into establishing these associations. It also provides data that are potentially useful to the dose-response and exposure assessment activities of the risk assessment process. Finally, nested case-control study designs can be applied to banked specimens to investigate hypotheses concerning disease risk factors and early biomarkers of exposure biomarkers of subclinical disease as has been done in many human serum banks.
